Acquired Resistant Mechanism of the First-generation EGFR TKIs

• Conditions: Non-small Cell Lung Cancer; Aquired Resistance; EGFR TKIs

• Registration Number: NCT02804217
• Lead Sponsor: Zhejiang Cancer Hospital

Brief Summary

Patients with advanced non-small-cell lung cancer (NSCLC) harboring sensitive epithelial growth factor receptor (EGFR) mutations invariably develop acquired resistance to EGFR tyrosine kinase inhibitors (TKIs). Identification of actionable genetic mutations can be helpful for guiding the subsequent treatment. This study aimed to analyze the genetic profile of NSCLC harboring acquired resistance to the first-generation EGFR TKIs using next generation sequencing (NGS).

Detailed Description

Not available

Study Timeline

• Status Verified: 2016-06
• Study Start: 2016-06
• Study First Submitted: 2016-06-14
• Study First Submitted QC: 2016-06-14
• Study First Posted: 2016-06-17
• Last Update Submitted: 2016-06-18
• Last Update Posted: 2016-06-21
• Primary Completion: 2017-06

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

• Histologically proven stage IIIB or IV non-small cell lung cancer
• patients harboring sensitive EGFR mutations and received first-generation EGFR-TKIs who developed acquired drug resistance
• patients who can provide pre-treatment (EGFR TKIs) tumor tissues
• patients with tumor lesions to be re-biopsy after drug resistance
• patients must sign an informed consent indicating that they are aware of the .investigational nature of the study in keeping with the policy of the hospital.

Exclusion Criteria

• History of another malignancy except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix
• patients with other systemic diseases

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
mutation profile	10 days

Trial Locations

Locations (1)

Zhejiang Cancer Hospital; 🇨🇳 Hangzhou, Zhejiang, China